-

PerkinElmer Introduces Next Generation, Automated Gas Chromatography Platform

GC 2400 solution streamlines performance and delivers superior precision for high throughput environments

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the GC 2400™ Platform, an advanced, automated gas chromatography (GC), headspace sampler and GC/mass spectrometry (GC/MS) solution designed to help lab teams simplify lab operations, drive precise results, and perform more flexible monitoring.

Created with productivity in mind for pharmaceutical, food, environmental and industrial analyses, the new platform brings together systems, software and a wide range of columns and consumables to meet customers’ varied workflow needs.

For high throughput lab environments and complex applications, the GC automated sampling capabilities reduces hands-on time and human error, and the industry-unique automated headspace/pneumatics technology delivers superior precision.

Monitoring single or multiple GC 2400 systems --inside or outside the lab -- is simple, using the wireless, touchscreen tablet interface running the PerkinElmer Simplicity Vision™ app.

The platform’s icon-driven, 21 CFR Part 11 compliant PerkinElmer SimplicityChrom™ Chromatography Data System (CDS) software reduces user training and guides teams through their entire GC workflow. The software interface is also customizable to address user’s unique data, notification and diagnostic needs.

With sustainability and safety in mind, built in sensors and a software-driven gas saver mode reduce operational gas consumption and support carrier gas alternatives such as hydrogen.

Commenting on the new offering, Suneet Chadha, VP and GM of Applied and Food Markets at PerkinElmer, said, “Today’s labs want their analytical workflows to command less time, attention and resources. Our new, automated GC 2400 Platform allows teams at any expertise level to better manage and monitor their GC analyses from sample through result so they can focus on high-value activities in their labs and businesses.”

PerkinElmer will highlight the new solution at Analytica Germany (Hall A2, booth 502) and Analytica Latin America (booth I037B) along with other offerings for life sciences, applied, diagnostics, food and more.

About PerkinElmer

PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5.0 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

Contacts

Media

Jennifer McNeil
Jennifer.Mcneil@perkinelmer.com
1 508.380.2902

Mary Karpa
Mary.Karpa@perkinelmer.com
1 215.896.4022

PerkinElmer, Inc.

NYSE:RVTY
Details
Headquarters: Waltham, Massachusetts
CEO: Prahlad Singh
Employees: 11,000
Organization: PUB

Release Summary
New PerkinElmer GC 2400 platform streamlines gas chromatography performance and delivers superior precision for high throughput environments  .
Release Versions

Contacts

Media

Jennifer McNeil
Jennifer.Mcneil@perkinelmer.com
1 508.380.2902

Mary Karpa
Mary.Karpa@perkinelmer.com
1 215.896.4022

More News From PerkinElmer, Inc.

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to acce...

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: UBS Global Healthcare Conference 2025 Monday, November 10, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Jefferies 2025 London Healthcare Conference Tuesday, November 18, 2025 2:00 p.m. GMT – Max Krakowiak Citi's 2025 Global Healthcare Conference Tuesday, December 2, 2025 9:00 a.m. ET – Prahlad Singh, president and chief execu...

Revvity Announces Financial Results for the Third Quarter of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025. The Company reported GAAP earnings per share of $0.40, as compared to $0.77 in the same period a year ago. Revenue for the quarter was $699 million, as compared to $684 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $82 million, as compared to $98 million for the same period a year ago. GAAP ope...
Back to Newsroom